HSBC ups Ranbaxy to overweight on generic Lipitor announcement
MUMBAI (Reuters) - HSBC raised its rating on shares of Ranbaxy Laboratories Ltd (RANB.NS) to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.
HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in U.S. sales.
Ranbaxy shares were up 3.3 percent as of 9:34 a.m.
(Reporting by Abhishek Vishnoi; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- UPDATE 3-Obama critic D'Souza spared prison for violating election law
- U.S. and Arab allies launch first strikes on militants in Syria
- Fired UPS worker kills two supervisors, self, in Alabama shooting
- New U.S. tax rules chill 'inversion' deal-making; shares dive |
- Chinese and Indian troops in Himalayan standoff
Retaining talent, reviving company
Infosys Ltd's new CEO has come up with a novel approach to reviving the financial fortunes of India's trailblazing outsourcing firm: use Facebook at work, tweet, but get the job done. Full Article